Quantitative promoter methylation differentiates carcinoma ex pleomorphic adenoma from pleomorphic salivary adenoma by Schache, A G et al.
Quantitative promoter methylation differentiates carcinoma
ex pleomorphic adenoma from pleomorphic salivary adenoma










1Department of Molecular & Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Daulby Street, Liverpool L69 3GN, UK;
2Regional Maxillofacial Unit, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, UK;
3Department of Histopathology, University of
Manchester, Oxford Road, Manchester M13 9WL, UK;
4Department of Oral Pathology, University of Liverpool, Pembroke Place, Liverpool L3 5PS, UK;
5Evidence-based Practice Research Centre, Edge Hill University, St Helens Road, Ormskirk, Lancashire L39 4QP, UK
BACKGROUND: Potential epigenetic biomarkers for malignant transformation to carcinoma ex pleomorphic adenoma (Ca ex PSA) have
been sought previously with and without specific comparison with the benign variant, pleomorphic salivary adenoma (PSA). Previous
analysis has been limited by a non-quantitative approach. We sought to demonstrate quantitative promoter methylation across
a panel of tumour suppressor genes (TSGs) in both Ca ex PSA and PSA.
METHODS: Quantitative methylation-specific real-time polymerase chain reaction (qMSP) analysis of p16
INK4A, CYGB, RASSF1, RARb,
human telomerase reverse transcriptase (hTERT), Wilms’ tumour 1 (WT1) and TMEFF2 gene promoters was undertaken on
bisulphite-converted DNA, previously extracted from archival fixed tissue specimens of 31 Ca ex PSA and an unrelated cohort of 28
PSA. All target regions examined had formerly been shown to be hypermethylated in salivary and/or mucosal head and neck
malignancies.
RESULTS: The qMSP demonstrated abnormal methylation of at least one target in 20 out of 31 (64.5%) Ca ex PSA and 2 out of 28
(7.1%) PSA samples (Po0.001). RASSF1 was the single gene promoter for which methylation is shown to be a statistically significant
predictor of malignant disease (Po0.001) with a sensitivity of 51.6% and a specificity of 92.9%. RARb, TMEFF2 and CYGB displayed
no apparent methylation, while a combinatory epigenotype based on p16, hTERT, RASSF1 and WT1 was associated with a
significantly higher chance of detecting malignancy in any positive sample (odds ratio: 24, 95% CI: 4.7–125, Po0.001).
CONCLUSIONS: We demonstrate the successful application of qMSP to a large series of historical Ca ex PSA samples and report on a
panel of TSGs with significant differences in their methylation profiles between benign and malignant variants of pleomorphic salivary
adenoma. qMSP analysis could be developed as a useful clinical tool to differentiate between Ca ex PSA and its benign precursor.
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Carcinoma ex pleomorphic adenoma (Ca ex PSA) is a rare and
poorly understood malignancy of salivary glands. It accounts for
3–4% of salivary neoplasms and approximately 12% of all salivary
malignancies (Gnepp, 1991). It has been suggested that Ca ex PSA
originates as a result of malignant transformation of ductal
epithelial and/or abluminal myoepithelial cells within pre-existing
pleomorphic salivary adenomas (PSA), the majority of which are
untreated or recurrent in nature (Eneroth and Zetterberg, 1974).
These cancers are typically high grade in nature, with frequent
metastasis, and have a poor prognosis (Lewis et al, 2001; Olsen
and Lewis, 2001).
Quantifying the risk of malignant transformation in PSA has not
been possible; however, there appears to be a temporal relation-
ship such that long-standing tumours have higher risk for
malignant transformation. This risk increases from 1.6% for
tumours present o5 years to 9.6% for PSA present in 415 years
(Ellis, 1996).
Understanding of the mechanisms underlying malignant trans-
formation from PSA to Ca ex PSA has been restricted by a paucity
of available tissue. A variety of molecular mechanisms and
potential biomarkers have been suggested in the context of various
salivary malignancies, with studies exploring differential expres-
sion of cyclin D1, p16, p53, EGFR, TGFa, Ki-67 and Mcm-2
by immunohistochemistry (Lewis et al, 2001; Augello et al, 2006;
Katori et al, 2007; Patel et al, 2007; Vargas et al, 2008). The role of
DNA-based biomarkers has not been extensively explored in this
setting. Individual mutations are generally uncommon; however,
the encouraging specificity and sensitivity of epigenetic bio-
markers has encouraged some studies comparing series of benign
and malignant salivary tumours (Maruya et al, 2004; Williams
et al, 2006; Lee et al, 2008). Earlier work was limited by the non-
quantitative methylation-specific real-time polymerase chain
reaction (MSP) techniques available (Maruya et al, 2003). The
merit of quantitative assays for promoter methylation status lies
in their ability to establish thresholds in the assessment of
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smethylation/non-methylation and potentially the classification of
benign and malignant counterparts. The case for pyrosequencing
methylation analysis (PMA) in salivary (Lee et al, 2008) and
squamous mucosal malignancy of the head and neck (Shaw et al,
2006) has been made when fresh frozen tissue is available. In the
case of archival samples in less common tumours, it is more likely
that fixed formalin paraffin-embedded (FFPE) tissue will be avail-
able. In such a situation the reduced integrity of DNA available
may restrict the potential advantages of PMA, while alternative
quantitative techniques such as real-time MSP (RT–MSP) (Eads)
may have a role (Lee et al, 2008).
An evaluation of tumour suppressor gene (TSG) promoter
hypermethylation limited to Ca ex PSA and its benign precursor
has not previously been performed. Such analysis may offer a
potential biomarker for progression, the basis for a diagnostic tool,
or further insight into the molecular mechanisms responsible. We
evaluate a large archival series of Ca ex PSA cases alongside
unrelated PSA using RT–polymerase chain reaction (PCR) to
quantify promoter methylation in seven TSGs previously shown to
be methylated in salivary and in epithelial malignancies, including
those of salivary origin.
MATERIALS AND METHODS
Case selection
The archives of the oral pathology laboratories of the Liverpool
and Manchester University Hospital Dental Schools were searched
using SNOMED code (M89413). Electronic databases were
searched from 1993 to 2007. Diagnosis was confirmed through
review of all potential H&E stained slides and cases with a
demonstrable pre-existing PSA or its ‘ghost’ were included in the
study (n¼24). Additional cases (n¼7) were also included in
which the clinical presentation indicated Ca ex PSA: history of a
long-standing stable swelling with recent rapid alteration in size
and with histological confirmation of a malignant tumour, usually
high grade and often showing multiple patterns of differentiation.
Presence of multiple patterns of malignant salivary gland type
tumours or diverse differentiation alone was not accepted
as definite evidence of Ca ex PSA. All cases were reviewed
independently by two pathologists (GH, JAW). Cases of PSA were
identified by database searching (SNOMED code M89400)
(n¼28).
Available FFPE blocks from the selected cases were retrieved.
The human tissue that formed the basis for this research
was utilised under previously granted ethical approval (Central
Liverpool) LREC 06/Q1505/71.
DNA extraction and bisulphite treatment
DNA extraction was undertaken using a modification of the
method reported by Banerjee et al (1995) for reasons of anticipated
reduced yield (complete details are available on request). The EZ
DNA Methylation kit (Zymo Research Corporation, Orange, CA,
USA) was used to bisulphite treat 2mg of previously prepared
DNA. The treated DNA was eluted in 50ml of 0.1 TE buffer.
qMSP analysis
Quantitative methylation-specific real-time polymerase chain
reaction was used to determine TSG methylation in each of the
samples. The gene promoters for p16
INK4A, CYGB, RASSF1, RARb,
human telomerase reverse transcriptase (hTERT), Wilms’ tumour
1 (WT1) and TMEFF2 were included in the panel for methylation
detection. The qMSP assays were designed using Primer Express
3.0 software (Applied Biosystems, Foster City, CA, USA). The
primer and probe sequences and PCR conditions used for these
real-time assays are given in Tables 1 and 2. A total reaction
volume of 25ml in each reaction contained Taqman Universal
Master Mix II (Applied Biosystems), 500nM of each primer, 250nM
of probe and 100ng of bisulphite-treated DNA. A separate assay
utilising a methylation-independent primer/probe set on the
b-actin gene (ACTB) was used to normalise for the DNA input
in each sample. Real-time PCR reactions were performed on an
Applied Biosystems 7500 FAST system. Serial dilutions (80–5%)
of in vitro methylated (SssI) human lymphocyte DNA made in
untreated lymphocyte DNA were used as a reference. DDCT values
were generated for each target after normalisation by ACTB
values. The RQ values were subsequently calculated (2
 DDCT) and
referenced to the artificially methylated samples for statistical
analysis. The associations between sample methylation and
tumour type (Ca ex PSA vs PSA) were tabulated, and Fisher’s
exact test was used to measure their significance. Duplicate
reactions were carried out for p16
INK4A, hTERT, WT1 and RASSF1.
Determination of positive results following duplicate reactions
for individual samples is detailed below.
Table 1 qMSP primer and probe sequences
Target F sequence R sequence Probe sequence
TMEFF2 GGAGAGTTAAGGCGTTTCGTAGTTC CCGACTACCTCTTCCCACGTAA CGAACGAACTAAAAAC
hTERT TTGGGAGTTCGGTTTGGTTTC CACCCTAAAAACGCGAACGA AGCGTAGTTGTTTCGG
WT1 GAGGAGTTAGGAGGTTCGGTC CACCCCAACTACGAAAACG AGTTCGGTTAGGTAGC
RARb GAGGATTGGGATGTCGAGAAC CTTACAAAAAACCTTCCGAATACG AGCGATTCGAGTAGGGT
RASSF1 TATTTTCGCGTGGTGTTTTGC CCCTTCCTTCCCTCCTTCG TCGTTGTGGTCGTTCG
CYGB GTGTAATTTCGTCGTGGTTTGC CCGACAAAATAAAAACTACGCG TGGGCGGGCGGTAG
P16
INK4A GGAGGGGGTTTTTTCGTTAGTATC CTACCTACTCTCCCCCTCTCCG AACGCACGCGATCC
Actin b GGGTGGTGATGGAGGAGGTT TAACCACCACCCAACACACAAT TGGATTGTGAATTTGTGTTTG
Abbreviations: hTERT¼human telomerase reverse transcriptase; qMSP¼quantitative methylation-specific real-time polymerase chain reaction; WT1¼Wilms’ tumour 1.
Details of forward (F), reverse (R) and probe sequences for each of the seven tumour suppressor genes analysed and for actin b.
Table 2 qMSP PCR conditions
Target Melting Annealing Extension
TMEFF2 951C, 15s 581C, 20s 601C, 40s
hTERT 951C, 15s 651C, 5s 621C, 45s
WT1 951C, 15s 621C, 60s
RARb 951C, 30s 651C, 5s 621C, 45s
RASSF1 951C, 15s 601C, 60s
CYGB 951C, 15s 641C, 5s 611C, 45s
P16
INK4A 951C, 15s 601C, 60s
Actin b 951C, 15s 581C, 20s 601C, 40s
Abbreviations: hTERT¼human telomerase reverse transcriptase; PCR¼polymerase
chain reaction; qMSP¼quantitative methylation-specific real-time polymerase chain
reaction; WT1¼Wilms’ tumour 1. Details of PCR conditions for each of the seven
tumour suppressor genes analysed and for actin b.
Promoter methylation in carcinoma ex pleomorphic adenoma
AG Schache et al
1847





















A threshold of 5% methylation was used to define positive
methylation above which a sample was deemed to be methylated at
that particular gene promoter. This was based on our previous
work for the minimum levels that are both biologically meaningful
and functionally relevant in non-microdissected tissues (Shaw
et al, 2006).
Duplicate experiments were undertaken for those gene promo-
ters demonstrating methylation in this sample set and each sample
was only deemed to be positive if methylation levels were above
5%. Where conflict existed between runs, the average methylation
level was utilised as a final arbiter (Table 3A and B).
Promoter methylation was observed in four of the seven gene
promoters included on the methylation panel (Figure 1). Methyl-
ation was demonstrated in a total of 20 out of 31 Ca ex PSA
samples (64.5%) and 2 out of 28 (7.1%) PSA samples (Po0.001).
The hTERT, WT1 and p16
INK4A methylation showed 12.9%, 9.7%
and 12.9% sensitivity, respectively, and 100% specificity (Table 4).
RARb, CYGB and TMEFF2 methylation was not apparent in any
sample (Figure 1). RASSF1 was the single gene promoter for which
methylation is shown to be a statistically significant predictor of
malignant disease (Po0.001) with a sensitivity of 51.6% and a
specificity of 92.9% (Table 4).
When aggregation of the results is undertaken, the presence of
methylation above the 5% threshold in hTERT, WT1, RASSF1 or
p16
INK4A was associated with a significantly higher chance of an
individual sample having malignant pathology (odds ratio: 24, 95%
CI: 4.7–125, P40.001). As a panel, the sensitivity for detecting
malignancy for any positive assay was 64.5% (95% CI: 45–81%)
and specificity for excluding benign disease was 92.9% (95% CI:
77–99%).
To determine whether positive methylation was occurring in an
interrelated manner, a goodness of fit calculation of observed vs




This study provides for the first time a comparative DNA
methylation profiling between Ca ex PSA and PSA. Owing to the
rarity of Ca ex PSA, the investigation was based on only 31 cases of
Ca ex PSA, even though the combined cases of two large British
cities constituting a population of around 7 million over 14 years
were used. Seven cases were included based on particular clinical
history and histopathological evidence of malignancy rather than
the histologically demonstrable presence of pre-existing/ghost of
PSA. It is noted that these cases gave comparable results with those
that did present with demonstrable PSA, which supports their
inclusion in the material.
Significant tumour-specific promoter methylation (for Ca ex PSA)
is apparent at RASSF1 by comparison with PSA. The remaining
promoters examined here, did not display, on a single marker
basis, statistically significant variation between tumour types.
However, a combinatory epigenotype consisting of hTERT, WT1,
RASSF1 and p16
INK4A (at least one positive) demonstrated a
positive predictive value for malignancy.
The concept of a CpG island methylator phenotype (CIMP) as
described in oral squamous mucosal cancer (Shaw et al, 2007) was
not apparent within this study as hypermethylation of individual
promoters occurs in a non-interrelated or independent manner.
It will though require a larger study incorporating a larger number
of promoters to substantiate the real frequency of CIMP in this
type of malignancy.
The high sensitivity (51.6%) of RASSF1 to detect malignant
disease is combined with an imperfect, albeit still high specificity
(92.9%). At this point, it is not clear whether this 7.1% of RASSF1
methylation-positive PSA cases represent false positives or benign
lesions with an elevated potential towards malignant transition to
Ca ex PSA. As none of these benign lesions were managed with
observation only, their malignant potential cannot be evaluated.
This possibility was alluded to by Williams et al (2006) in their
description of the role of TSG hypermethylation in salivary gland
tumourigenesis. This series reported 8.7% cases with methylation
in benign tumours compared with 27% of malignant cases,
although no data on Ca ex PSA was available. Lee et al (2008),
in their comparative analysis of methylation techniques, found
RASSF1 to be methylated in 35% of 69 malignant salivary tumours
and 50% of Ca ex PSA, although only six cases were available.
RASSF1 (Ras association domain-containing protein 1) gene
encodes a protein similar to the RAS effector proteins. The
encoded protein interacts with DNA repair protein XPA and
inhibits the accumulation of cyclin D1, thus inducing cell cycle
arrest (Shivakumar et al, 2002). Loss or altered expression of this
gene has been associated with the pathogenesis and progression of
a variety of cancers (Burbee et al, 2001; Donninger et al, 2007;
Buckingham et al, 2010) including oral SCC (Ghosh et al, 2008;
Huang et al, 2009).
There are no reported studies exploring quantitative methyla-
tion of p16
INK4A in salivary malignancy, which is surprising as it
appears to be implicated in a wide variety of cancer types, often
offering a high degree of specificity. We have previously shown
that p16
INK4A is hypermethylated in 28% of oral squamous cell
carcinomas (OSCCs) compared with 4% of surrounding unaffected
margins (Shaw et al, 2006). In addition, p16
INK4A promoter
methylation was detected in 57% of oral epithelial dysplasias
undergoing malignancy in comparison with 8% of those which did
not transform (Hall et al, 2008). In this study, p16
INK4A offered
100% specificity and 12.9% sensitivity in determining Ca ex PSA
from PSA. A previous study reported p16
INK4A hypermethylation
in 14% of a series of 28 PSA and 100% in five salivary carcinomas,
one of which was Ca ex PSA (Augello et al, 2006). This study used a
non-quantitative MSP approach, most probably reflecting the
higher rate of positives. The need for quantitative assays in the
determination of clinically meaningful threshold values is widely
accepted to date.
Human telomerase reverse transcriptase is a component of the
telomerase ribonucleoprotein complex and is tightly regulated,
such that it is not normally detectable in the majority of somatic
cells. As almost all human cancer cells express telomerase while
most normal cells do not, the hTERT promoter has been
characterised as a molecular switch for the selective expression
of target genes in tumour cells (Takakura et al, 1999). Within our
cohort of salivary tumours, hTERT promoter methylation was
apparent in only 12.9% of Ca ex PSA and absent in PSA. Previous
reference to hTERT activity in head and neck cancer has been with
respect to OSCC and related mucosal dysplasia. In particular, using
RT–PCR expression analysis, Pannone et al (2007) found 66% of
OSCC tumours to be overexpressing hTERT by comparison with
normal tissues. The hTERT promoter hypermethylation has been
implicated in cervical cancer progression while not correlating
with down-regulation hTERT expression (Widschwendter et al,
2004; Iliopoulos et al, 2009; Kumari et al, 2009). It has been
postulated that methyl-CpG-binding domain proteins aberrations
may be responsible for this paradox (Chatagnon et al, 2009).
Wilms’ tumour 1 gene encodes for a protein essential for normal
urogenital development, but it has been shown to be overexpressed
in several epithelial tumours and tumour cell lines including head
and neck squamous cell carcinoma (Oji et al, 1999, 2003).
Abnormal expression of WT1 was shown in 7% of benign and
31% of malignant salivary tumours (Nagel et al, 2003), none of
which were Ca ex PSA, while expression was not detected in
normal adjacent salivary tissue. Conversely, WT1 gene hyper-
methylation has been observed in cervical and colorectal cancer
and has been shown to correlate with reduced WT1 expression in
ovarian clear cell carcinoma (Kaneuchi et al, 2005; Lai et al, 2008).
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sFurthermore, our preliminary methylation array analysis on oral
SCC has identified WT1 among potential prognostic biomarkers
(unpublished data). Thus, the control of the WT1 gene may differ
in cancers from different sites. In the present investigation,
analysis of WT1 promoter methylation failed to demonstrate
methylation in any PSA samples and o10% of Ca ex PSA samples
Table 3 Average DDCT and RQ for each (a) Ca ex PSA sample and (b) PSA sample
hTERT WT1 RASSF1 p16 RARb CYGB TMEFF2
Sample DDCT RQ DDCT RQ DDCT RQ DDCT RQ DDCT RQ DDCT RQ DDCT RQ
5% Control 7.9 1.0 5.6 1.0 5.2 1.0 5.7 1.0 9.5 1.0 4.5 1.0 6.2 1.0
(A) Ca ex PSA 0.0 0.0 0.0 0.0 1.4 14.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
9.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
6.9 2.0 0.0 0.0 1.1 16.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 5.3 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
3.7 18.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
8.1 0.9 0.0 0.0 5.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10.5 0.2 0.0 0.0 8.6 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
5.6 4.9 0.0 0.0 1.2 15.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 5.3 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10.5 0.2 0.0 0.0 2.9 4.9 4.2 2.9 0.0 0.0 0.0 0.0 0.0 0.0
7.7 1.1 8.0 0.2 3.9 2.4 5.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0
9.4 0.4 8.7 0.1 3.1 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 8.5 0.1 8.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
9.6 0.3 10.0 0.0 2.9 4.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
12.8 0.0 0.0 0.0 4.1 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10.5 0.2 0.0 0.0 2.1 8.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
9.7 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
12.5 0.0 0.0 0.0 4.4 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 4.3 2.5 4.9 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
8.9 0.5 0.0 0.0 5.2 1.0 4.1 3.0 0.0 0.0 0.0 0.0 0.0 0.0
8.5 0.6 7.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
8.2 0.8 6.1 0.7 3.3 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 6.5 0.5 4.3 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 3.6 2.9 6.8 0.5 0.0 0.0 0.0 0.0 0.0 0.0
13.8 0.0 10.0 0.0 5.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
11.8 0.1 4.1 2.9 0.0 0.0 5.1 1.5 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
12.9 0.0 0.0 0.0 4.4 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
(B) PSA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
15.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
11.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
9.9 0.2 0.0 0.0 12.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 9.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
10.3 0.2 0.0 0.0 12.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 10.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 5.3 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 5.1 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 8.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
14.1 0.0 0.0 0.0 7.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 8.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 11.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 5.6 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 11.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
12.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 12.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0 4.5 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
16.8 0.0 8.1 0.2 6.1 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Abbreviations: Ca ex PSA¼carcinoma ex pleomorphic adenoma; hTERT¼human telomerase reverse transcriptase; PSA¼pleomorphic salivary adenoma; qMSP¼quantitative
methylation-specific real-time polymerase chain reaction; WT1¼Wilms’ tumour 1. qMSP results for each sample by tumour suppressor gene. Each result is referenced to the
artificially 5% methylation control sample (RQ¼2
 DDCT).
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swere methylated at this promoter. The utility of this biomarker
in salivary cancer is thus limited to its use in a panel.
Our investigation further demonstrates the ability to gain
quantitative methylation data from archival samples. Despite the
acknowledged limitations in DNA quality from archival material,
qMSP successfully provided reliable and reproducible results
across several assays.
Most individuals presenting with PSA are advised to undergo
resection of the tumour to exclude the relative risk of malignant
transformation. A marker for malignant progression to Ca ex PSA
from PSA would be of significant benefit to these individuals as
any risk would, therefore, become quantifiable.
At present, fine needle aspirate cytology (FNAC) is a major
component in the diagnosis of salivary tumours, particularly those
arising in the parotid gland. Klijanienko et al (1999) explored
the diagnostic pitfalls and considerations of this technique in
Ca ex PSA and found that although it was accurate in diagnosis of
histologically high-grade Ca ex PSA, sensitivity and specificity fell
in lower-grade Ca ex PSA. To avoid these diagnostic difficulties, it
is possible to envisage a panel of genes applied as a useful adjunct
to such FNAC samples or equally to core biopsies, which have been
impossible to diagnose or grade on histological grounds alone. The
results of this study highlight significant differences in methylation
between the benign and malignant tumour type and a broader
array of validated methylation biomarkers might constitute a
valuable diagnostic tool.
With less constrained resources, in particular original sample
DNA, innovative techniques such as methylation microarray
technology could be used to highlight further targets worthy of
investigation and validation as part of a more extensive panel of
TSGs. It is, however, unlikely that a comprehensive and specific
methylation panel could ever be economically validated for such a
rare tumour site such as Ca ex PSA; however, research in more
common tumour sites may add significantly to this process. As an
example, the impressive sensitivity and specificity of GSTP1
methylation in prostate adenocarcinoma (Jeronimo et al, 2001) has
led to a variety of studies in its clinical use.
In common with other clinical sites, the management of benign
salivary neoplasms includes complex surgery in an attempt to
avoid the unpredictable risks of future malignant transformation.






































































hTERT WT1 RASSF1 p16 RAR CYGB TMEFF2
Figure 1 qMSP results. Representation of qMSP data for Ca ex PSA (left) and PSA (right) samples. ’, Promoter methylation positive; , Promoter
methylation negative (at 5% methylation threshold). Data from hTERT, WT1, RASSF1 and p16 data is from duplicate experiments.
Table 4 Performance of single promoter methylation as biomarkers of malignant transformation of PSA to Ca ex PSA
hTERT WT1 RASSF1 p16 RARb CYGB TMEFF2
Sensitivity (%) 12.9 9.7 51.6 12.9 0 0 0
Specificity (%) 100 100 92.9 100 100 100 100
Difference between benign and malignant (Fisher’s exact) P¼0.11 P¼0.24 Po0.001 P¼0.11 — — —
Abbreviations: Ca ex PSA¼carcinoma ex pleomorphic adenoma; hTERT¼human telomerase reverse transcriptase; PSA¼pleomorphic salivary adenoma; WT1¼Wilms’
tumour 1. Sensitivity and specificity for each tumour suppressor gene as a test for malignancy in a sample.
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sIt is hoped that the accumulation and validation of data such as is
presented here might allow a more conservative approach in the
future. Such validation of a methylation biomarker panel may,
therefore, have diagnostic, prognostic and therapeutic importance
in the management of both the benign and malignant variants of
this salivary tumour.
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